Physician profile
William C Harrell
NPI 1083673685
$2,353.19
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $433 · 2021: $476 · 2022: $568 · 2023: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $593.86 | 2019-2023 | Trulicity, Mounjaro, Lyumjev |
| Novo Nordisk INC | $249.10 | 2019-2023 | Ozempic, Rybelsus |
| Mannkind Corporation | $229.15 | 2020-2023 | Afrezza |
| Abbvie INC. | $221.46 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.35 | 2021-2023 | |
| Galderma Laboratories, L.P. | $125.13 | 2023 | |
| Sanofi-Aventis U.S. LLC | $109.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.63 | 2022-2023 | Jardiance, Tradjenta, Synjardy |
| Ibsa Pharma INC. | $88.82 | 2020-2021 | |
| Dexcom, INC. | $79.02 | 2021-2022 | |
| Allergan, INC. | $73.25 | 2020 | |
| Abbott Laboratories | $65.80 | 2021-2022 | |
| Medtronic, INC. | $49.41 | 2022-2023 | Inpen Smart Insulin Delivery System |
| Ironshore Pharmaceuticals INC. | $43.89 | 2019 | |
| Merck Sharp & Dohme LLC | $36.18 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $35.94 | 2023 | |
| Janssen Pharmaceuticals, INC | $28.30 | 2019 | |
| Halozyme INC | $23.52 | 2023 | |
| Exact Sciences Corporation | $23.18 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $20.74 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $17.46 | 2019 | |
| Gilead Sciences, INC. | $16.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.